Document is current
Any future updates will be listed below
-
Authors
Schneeweiss-Gleixner, Mathias
Krenn, Katharina
Petter, Mathias
Haselwanter, Patrick
Kraft, Felix
Adam, Lukas
Semmler, Georg
Hartl, Lukas
Halilbasic, Emina
Buchtele, Nina
Krall, Christoph
Staudinger, Thomas
Zauner, Christian
Trauner, Michael
Stättermayer, Albert Friedrich
- License Information
-
More Information
Article History
Received: 16 April 2024
Accepted: 23 September 2024
First Online: 8 October 2024
Declarations
:
: The authors declare no competing interests.
: M.T. received speaker fees from BMS, Falk Foundation, Gilead, Intercept, Ipsen, Jannsen, Madrigal, MSD and Roche; he advised for Abbvie, Agomab, Albireo, BiomX, Boehringer Ingelheim, Chemomab, Cymabay, Falk Pharma GmbH, Genfit, Gilead, Hightide, Intercept, Janssen, LoopLab, Mirum, MSD, Novartis, Phenex, Pliant, Rectify, Regulus, Siemens and Shire. He further received travel support from Abbvie, Falk, Gilead, Intercept and Jannsen and research grants from Albireo, Alnylam, Cymabay, Falk, Genentech, Gilead, Intercept, MSD, Takeda and UltraGenyx. He is also co-inventor of patents on the medical use of norUDCA filed by the Medical Universities of Graz and Vienna. K.K. received research grants from Apeptico, Biotest, Bayer and Alterras and travel support from Biotest.
: The study was approved by the local Ethics Committee of the Medical University of Vienna (EK 1872/2021). Given the retrospective design of the study, informed consent statements are not required.
